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Abstract: Background Chronic cocaine users (CU) display reduced peripheral expression of the gluco-
corticoid receptor gene (NR3C1), which is potentially involved in stress-related psychiatric symptoms
frequently occurring in CU. However, it is unknown whether psychiatric symptoms and lower NR3C1
expression are related to each other and whether reduction of drug consumption reverse them. Method
At baseline, NR3C1 mRNA expression was measured in 68 recreational CU, 30 dependent CU, and
68 stimulant-naïve controls. Additionally, the Revised Symptom Checklist (SCL-90R) and the Barratt
Impulsiveness Scale (BIS) were assessed. At a one-year follow-up, the association between change in
NR3C1 expression and psychiatric symptoms was examined in 48 stimulant-naïve controls, 19 CU who
increased and 19 CU who decreased their consumption. At both test sessions, cocaine concentrations in
hair samples were determined. Mixed-effects models were used to investigate how changes in drug use
intensity affect severity of psychiatric symptoms and NR3C1 expression over time. Results At baseline,
recreational and dependent CU displayed elevated impulsivity and considerable symptom burden across
most of the SCL-90R subscales. Time-group interaction effects were found for several impulsivity scores,
SCL-90R Global Severity Index, Paranoid Thoughts, and Depression subscales as well as for NR3C1
expression. Pairwise comparisons showed that decreasing CU specifically improved in these SCL-90R
subscales, while their NR3C1 expression was adapted. Finally, changes in NR3C1 expression were neg-
atively correlated with changes in impulsivity but not SCL-90R scores. Conclusion Our findings suggest
that NR3C1 expression changes and some psychiatric symptoms are reversible upon reduction of cocaine
intake, thus favouring abstinence-oriented treatment approaches.
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Background: Chronic cocaine users (CU) display reduced peripheral expression of the 
glucocorticoid receptor gene (NR3C1), which is potentially involved in stress-related psychiatric 
symptoms frequently occurring in CU. However, it is unknown whether psychiatric symptoms 
and lower NR3C1 expression are related to each other and whether reduction of drug 
consumption reverse them. 
Method: At baseline, NR3C1 mRNA expression was measured in 68 recreational CU, 30 
dependent CU, and 68 stimulant-naïve controls. Additionally, the Revised Symptom Checklist 
(SCL-90R) and the Barratt Impulsiveness Scale (BIS) were assessed. At a one-year follow-up, 
the association between change in NR3C1 expression and psychiatric symptoms was examined in 
48 stimulant-naïve controls, 19 CU who increased and 19 CU who decreased their consumption. 
At both test sessions, cocaine concentrations in hair samples were determined. Mixed-effects 
models were used to investigate how changes in drug use intensity affect severity of psychiatric 
symptoms and NR3C1 expression over time. 
Results: At baseline, recreational and dependent CU displayed elevated impulsivity and 
considerable symptom burden across most of the SCL-90R subscales. Time-group interaction 
effects were found for several impulsivity scores, SCL-90R Global Severity Index, Paranoid 
Thoughts, and Depression subscales as well as for NR3C1 expression. Pairwise comparisons 
showed that decreasing CU specifically improved in these SCL-90R subscales, while their 
NR3C1 expression was adapted. Finally, changes in NR3C1 expression were negatively 
correlated with changes in impulsivity but not SCL-90R scores. 
Conclusion: Our findings suggest that NR3C1 expression changes and some psychiatric 




Cocaine use is frequently accompanied by psychiatric symptoms (Rounsaville et al., 
1991), neuropsychological deficits (Jovanovski et al., 2005; Vonmoos et al., 2013b), 
neurological disorders (Treadwell and Robinson, 2007) and other medical conditions, such as 
infectious and cardiovascular diseases (Benowitz, 1993), which all contribute to diminished 
quality of life and disrupted social networks, and to increased high-risk behaviour and worsened 
prognosis (Degenhardt and Hall, 2012; Preller et al., 2014; Whiteford et al., 2013). Particularly, 
the high prevalence of psychiatric symptoms in cocaine users (CU) contributes to the 
maintenance of substance use by inducing a more debilitated primary condition and by 
promoting adverse life situations (Kessler et al., 2005). This idea is supported by cumulative 
cross-sectional evidence associating cocaine use with, for instance, post-traumatic stress 
symptoms (Tull et al., 2016; Welsh et al., 2017), mood symptoms, anxiety symptoms (Roy et al., 
2015), and attention-deficit/hyperactivity disorder (ADHD) (Perez de Los Cobos et al., 2011). 
Retrospective analyses (Glantz et al., 2009) and a few prospective studies (Zimmermann et al., 
2003) (Costello et al., 2003) suggest that psychiatric disorders such as anxiety and conduct 
disorder can predict onset of substance use, leading researchers to assume that substance 
consumption might emerge as an attempt to “self-medicate” (Kessler et al., 2012; Lazareck et al., 
2012). However, on the basis of cross-sectional data, it has also been proposed that affective 
symptoms specifically follow the onset of cocaine use, while anxiety, antisocial personality 
disorder and ADHD characteristics typically exist before (Rounsaville et al., 1991).  
Although the self-medication hypothesis has been supported by a few prospective studies, 
reciprocal associations, in which cocaine use is considered as a specific predictor of later onset of 
psychiatric symptoms, have scarcely been investigated. A European multicentre study reported 
that the intensity of cocaine use predicted worse mental health, together with physical health and 
social vulnerability (Haasen et al., 2005). Similarly, a 6-year prospective study investigating the 
longitudinal effects of HIV in a CU sample found that heavy cocaine consumption was 
associated with an increase in depressive symptoms and that CU reported an annual worsening of 
depression scores (Mukerji et al., 2017). However, these previous studies are exclusively based 
on self-report assessments of illicit substance use, which can markedly underestimate the true 
substance consumption (Magura, 2010). Additionally, most longitudinal studies have not 
specifically investigated the effects of cocaine consumption changes on psychiatric symptoms, 
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instead reporting these symptoms as secondary outcomes. Therefore, it remains unclear whether 
psychiatric symptoms can be induced by chronic cocaine use and also be reversed if cocaine 
consumption is discontinued or attenuated.  
Remarkably, it has been suggested that the deleterious effect of cocaine use on mental 
health may be partially explained by the fact that cocaine acts as a pharmacological stressor, 
strongly activating the hypothalamic-pituitary-adrenal (HPA) axis, one of the main stress 
response systems in the human body (Kirschbaum et al., 2009). Accordingly, cocaine 
consumption stimulates various neurotransmitter pathways, including via the activation of 
dopaminergic neurons, and strongly increases the release of cortisol from the adrenal glands 
(Deroche-Gamonet et al., 2003). The genomic effects of cortisol are mediated via the 
glucocorticoid receptor (GR, encoding gene NR3C1), which regulates the expression of target 
genes and is thought to be involved in the development of addiction via its interaction with the 
dopaminergic system (Ambroggi et al., 2009; Deroche-Gamonet et al., 2003). It has already been 
shown that NR3C1 polymorphisms together with dopamine-related genetic variations have direct 
effects on the functioning of the prefrontal cortex (El-Hage et al., 2013), and thus possibly on the 
regulation of behavioural control in psychiatric disorders (Arnsten, 2006). Recently, a lower 
expression of NR3C1 mRNA has been associated with cocaine use (Schote et al., 2019) and 
several functional variants of NR3C1 have been associated with higher risk for depression, 
reduced responses after antidepressant therapy (Spijker and van Rossum, 2012), ADHD (Fortier 
et al., 2013; Schote et al., 2016) and cocaine addiction (Schote et al., 2019). Complementarily, it 
has been suggested that the glucocorticoid receptor system constitutes one of the key 
mechanisms affecting reward sensitivity and influencing individual susceptibility to addiction 
(Goeders and Clampitt, 2002), increasing the vulnerability to relapse via behavioural 
disinhibition (Diaz-Marsa et al., 2008; Finy et al., 2014; Maniaci et al., 2018). Accordingly, we 
have previously proposed that cocaine directly downregulates NR3C1 expression by its excessive 
stimulation of cortisol secretion, which likely contributes to a reduced stress responsivity, 
increased impulsivity, and a higher burden with stress-related psychiatric disorders such as 
affective symptoms (Schote et al., 2019). 
In this study, we therefore aimed to examine the longitudinal association between 
objective changes in cocaine consumption and psychiatric symptoms measured with the Revised 
Symptom Checklist-90 (SCL-90R) in groups of CUs with decreased (“decreasers”) or increased 
5
cocaine use (“increasers”) after a 1-year interval. Because we have previously shown that self-
reported impulsivity, cluster B personality disorder symptoms, as well as facets of social and 
non-social cognition can covary with changing cocaine use (Hulka et al., 2015; Vonmoos et al., 
2019; Vonmoos et al., 2014) – indicating that decreased cocaine use is often associated with 
improvements of cognitive impairments, impulsivity, and personality disorder symptoms within 
one year – here we expected that reducing cocaine use would also be associated with the 
attenuation of psychiatric symptoms as measured with the SCL-90R. Additionally, we aimed to 
investigate the change in peripheral expression of the NR3C1 mRNA in response to changes in 
cocaine use and the relation of these changes to variations in psychiatric symptom burden. 
Hence, considering that i) NR3C1 gene expression was correlated with severity of cocaine 
consumption (Schote et al., 2019); and ii) lowered NR3C1 mRNA concentrations were correlated 
with increased total scores on the positive symptom scale of the SCL-90R in CU (Schote et al., 
2019) and diagnosis of major depressive disorder (Spindola et al., 2017); we expected NR3C1 
gene expression to covary with changes in cocaine use and the severity of self-reported 
psychiatric symptoms including impulsivity. Finally, we aim to overcome preceding limitations 
arising from self-reported drug use measures by combining drug use self-reports with objective 
urine tests and hair toxicology analysis, as already employed in previous analyses of this sample 
(Hulka et al., 2015; Vonmoos et al., 2019; Vonmoos et al., 2014). 
Materials and Methods 
Participants 
Within the context of the Zurich Cocaine Cognition Study (ZuCo
2
St) (Vonmoos et al., 
2013a), a total sample of 166 participants (98 CU and 68 stimulant-naïve controls) was analysed 
at baseline (T1). CU were included if cocaine was their primary drug of choice, they currently 
used more than 0.5g per month and were not abstinent for more than 6 months. At baseline, 
exclusion criteria for all participants were any current or previous neurological disorders or head 
injuries and severe somatic diseases. Controls were excluded if they presented with current or 
previous DSM-IV Axis I psychiatric disorders (except for nicotine addiction), or regular illegal 
drug use (>15 occasions lifetime, except for recreational cannabis use). Additional exclusion 
criteria for CU were use of opioids, a polytoxic drug use pattern according to DSM-IV, and 
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DSM-IV Axis I adult psychiatric disorders – except for cocaine, cannabis, nicotine, and alcohol 
abuse/dependence; history of affective disorders (current major depression was also 
exclusionary); and attention deficit hyperactivity disorder (ADHD).  
The follow-up measurement (T2) took place approximately one year after baseline 
(average number of weeks between T1 and T2 for controls = 58.2, SD = 10.1; average number of 
weeks between T1 and T2 for CU = 62.0, SD = 14.3). One hundred and thirty-two participants 
agreed to be re-tested at follow-up, but 46 participants (41 CU, 5 controls) had to be excluded 
from the final analyses due to hair analyses revealing illegal drug use not allowed by our 
exclusion criteria, or a relatively stable cocaine use pattern that did not meet criteria for either 
increase or decrease (see below). Ultimately, 86 participants (38 chronic CU and 48 stimulant-
naïve controls) were suitable for inclusion in the final analysis (Hulka et al., 2015; Vonmoos et 
al., 2019; Vonmoos et al., 2014). 
The test procedure was similar in baseline and follow-up (Vonmoos et al., 2014). 
Additionally, because gene expression can be influenced by circadian rhythm (Sukumaran et al., 
2010), all blood samples were collected between 10am and 2pm. Before, test sessions (T1 and 
T2) participants from both groups were asked to abstain from illegal substances for at least 72h 
and from alcohol for 24h, and compliance with these instructions was controlled using urine 
screenings (for technical details see Vonmoos et al., 2013). Additionally, at both test sessions 
participant’s self-report and drug use severity were confirmed with quantitative toxicological 
analysis of hair samples using liquid chromatography tandem mass spectrometry (Vonmoos et al. 
2014). The Cantonal Ethics Committee of Zurich approved the study (E-14/2009). All 
participants provided written informed consent and received compensation for their participation. 
Group assignment  
At baseline, because we were interested in investigating whether the severity of cocaine 
use was related to the severity of psychiatric symptoms, CU were characterized as either 
relatively pure recreational CU (RCU, n=68) or dependent CU (DCU, n=30). Cocaine 
dependency was diagnosed according to the Structured Clinical Interview for DSM-IV-R Axis I 
Disorders (SCID-I) (Vonmoos et al., 2013a). At follow-up, CU were characterized as either 
increasers (participants who consumed substantially more cocaine within 1-year follow-up, 
n=19) or decreasers (participants who consumed substantially less cocaine within 1-year follow-
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up, n=19). The assignment criteria were based on the combination of absolute and relative 
changes in cocaine concentration in hair samples between T1 and T2, as previously described in 
detail by Vonmoos et al. (2014). The absolute criterion refers to a change of at least ±0.5 ng/mg 
in cocaine concentration according to the accepted cut-off value for reliable detection of cocaine 
use (Bush, 2008; Cooper et al., 2012). The relative criterion was based on a minimum increase of 
20% or a minimum decrease of 10% in the hair toxicology parameter cocainetotal (i.e., cocaine + 
benzoylecgonine + norcocaine) (Hoelzle et al., 2008). Cocaine increasers showed a mean 
increase of +30.4 ng/mg (+297%), range +0.5 to +268.5 ng/mg (+20% to +5374%), SD 61.9 
ng/mg, whereas cocaine decreasers showed a mean decrease of-10.6 ng/mg (-72%), range -116.9 
to -0.6 ng/mg (-100% to -12%), SD 26.7 ng/mg (Vonmoos et al. 2014).  
Clinical assessments 
All participants were examined by trained psychologists using the SCID-I (APA, 1994) at 
baseline and follow-up. At both test sessions, current (average use during the last 6 months) and 
lifetime (or in the last year, for T2) self-reported drug use was assessed by the structured and 
standardized Interview for Psychotropic Drug Consumption (IPDC; Quednow et al., 2004). The 
severity of psychiatric symptoms and current psychological distress was assessed by the SCL-
90R (Derogatis and Cleary, 1977). The SCL-90R includes 90 items related to psychological 
health and contains nine subscales (Aggressiveness, Anxiety, Depression, Obsessive-compulsive, 
Paranoid ideation, Phobic anxiety, Psychoticism, Somatization, and Uncertainty to social 
contact) and three indices of global wellness (Global Severity Index [GSI], Positive Symptoms 
Total [PST], and Positive Symptom Distress Index, [PSDI]). The GSI is the average of all 
ratings, while the PST is used to report the overall number of self-reported symptoms (>0), and 
the PSDI indicates the average intensity of symptoms (Derogatis and Cleary, 1977). Finally, the 
Barratt Impulsiveness Scale (BIS) was used to assess self-reported impulsivity by extracting the 
total score and the three main factors: attentional, motor, and non-planning impulsiveness (Patton 
et al., 1995). Baseline and longitudinal results regarding the BIS in the present sample have been 
published previously (Hulka et al., 2015; Vonmoos et al., 2013a), however, the longitudinal 
analysis was done with a set of different predictors and with another reference group (increasers 
instead of controls) (Hulka et al., 2015). 
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Gene expression analysis 
Total RNA was isolated from whole blood using the RNA isolation NucleoSpin RNA 
blood in combination with the NucleoSpin RNA/DNA buffer according to the manufacture´s 
recommendations (Macherey-Nagel AG, Oersingen, Switzerland). Purity and quantity of total 
RNA was determined spectrophotometrically (NanoVue, GE Healthcare Life Sciences), and 
RNA quality given as RNA integrity number (RIN) values was measured on the automated 
electrophoresis system (Experion, BioRad Co., Hercules, CA, USA). Per sample, 500 ng of total 
RNA were reverse transcribed into cDNA using the iScript cDNA synthesis kit (BioRad Co., 
Hercules, CA, USA). Gene expression analysis of NR3C1 was performed using the QuantiTect 
SYBR green detection method (Qiagen, Hombrechtikon, Switzerland), a quantitative real-time 
reverse-transcription polymerase chain reaction with NR3C1 specific detection primers 
(QT00012915) and four reference genes ACTB, ALAS1, GAPDH, and PPIA for normalization 
(Qiagen). PCR specificity was confirmed using melting curve analyses for each triplicate. Gene 
expression and normalization analysis was conducted using the qBase plus software (Biogazelle, 
The Netherlands), which uses a special algorithm originating from the geNORM (Vandesompele 
et al., 2002) to integrate the most stable RG together into a normalization value, for further 
details see Havranek et al. (2015). Furthermore, to minimize the possibility of technical issues or 
batch effects, both blood samples, baseline and follow-up, were analysed at the end of the study 
and gene expressions were assessed on the 384 well plates using the same chemicals (bath) and 




Demographic data, drug use patterns, and frequency data were analysed with analyses of 
variance (ANOVAs), Student’s t-tests, and Pearson’s χ2-test using the Statistical Package for the 
Social Sciences 25 (SPSS 25, IBM). Spearman rank correlations were performed to explore how 
cocaine hair concentration values relate to use self-report consumption pattern. 
Cross-sectional analyses: ANOVAs were initially performed to investigate whether 
stimulant-naïve controls differ from RCU and DCU concerning SCL-90R and NR3C1 mRNA 
expression. Next, to investigate the estimation on the severity of cocaine consumption accessed 
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with hair toxicology analysis and NR3C1 mRNA expression in both RCU and DCU a Spearman 
rank correlation was performed.  
Longitudinal analyses: first, a series of linear mixed models (also known as linear 
multilevel models, random-effects, or random-coefficient models) were performed to investigate 
the association between changes in cocaine use, psychiatric symptoms and NR3C1 expression 
over time (at T1 and T2) (Gill, 2000). Predictors (fixed-effects) evaluated were group (i.e., 
increasers, decreasers and controls), time (i.e., dummy variable with levels “baseline” and 
“follow-up”), and time-group interaction. At follow-up, because participants were asked whether 
they had attended any treatment (i.e., outpatients or impatient units), a dummy variable (i.e., 
treatment ‘yes’ or ‘no’) was included in the model as a random-effect. A random intercept effect 
was also modelled for each participant allowing us to control for individual mean differences at 
baseline (Harrison et al., 2018). Additional post hoc comparisons were performed using 
Student’s t-tests and effect sizes were calculated by Pearson’s correlation coefficient (r <.10 
small effect size; r <.30 medium effect size; r <.50 large effect size) (Cohen, 1992).  
In a second step, the same models were performed to investigate the possible effects of 
age, sex, years of school education, alcohol consumption, nicotine consumption, cannabis 
consumption, cocaine dependency diagnosis, and seasonal variation in NR3C1 mRNA 
expression. Moreover, to investigate the possibility of technical issues or batch effects when 
performing the NR3C1 mRNA expression, similar linear mixed models were also performed for 
the reference genes expression. Finally, Spearman rank correlations were performed within the 
increaser group (n=19), the decreaser group (n=19), and a combined user group (n=38) to 
investigate whether changes in cocaine consumption and changes in NR3C1 mRNA expression 
were associated with changes in psychiatric symptoms.  
The linear mixed models and Spearman rank correlations were performed with the open 
source statistical software R (R Core Team, 2015).  
Results 
Demographic Characteristics and Drug Use Patterns at Baseline 
As previously shown for this sample (Vonmoos et al., 2013a; 2013b), controls, RCU and 
DCU did not differ concerning age, sex, and estimated verbal IQ (Table S1). Regarding the 
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longitudinal sample, cocaine increasers and decreasers did not significantly differ regarding age, 
sex, verbal IQ, years of education, smoking status, and length of interval between the two study 
assessments (Table S2). As also reported by Vonmoos et al. (2014), at baseline, increasers and 
decreasers displayed similar cocaine hair concentrations. However, hair analyses for increasers 
showed a 3-fold increase between baseline and follow-up, while decreasers displayed a quarter 
of the cocainetotal hair concentration after one year (Figure S1). As shown in Vonmoos et al. 
(2013) before, Spearman rank correlations revealed that total hair concentration of cocaine 
metabolites (Cocainetotal) positively correlated with self-reported estimated cumulative dose 
(r=.518, p<.001, n=96), and duration of use (r=.386, p<.001, n=96).  
Psychiatric Symptoms Severity and NR3C1 mRNA Expression at Baseline 
At baseline, we found significant group differences regarding all SCL-90R subscales 
(Table 1). Post hoc comparisons revealed that RCU differed from controls in the main index 
scores GSI (Figure 1), PSDI and PST, as well as in the subscales of Aggressiveness, Anxiety, 
Compulsiveness, and Somatization, while DCU differed from controls in all symptoms except 
for Paranoid Thoughts and Psychoticism. Additionally, DCU differed from RCU concerning the 
GSI (Figure 1), PSDI, PST, Anxiety, Compulsiveness, Depression, somatization and uncertainty 
to social contact. As published before (Vonmoos et al 2013b), both RCU and DCU showed 
elevated BIS scores, however, values are shown again here for the sake of thoroughness and 
clarity. 
Regarding the NR3C1 mRNA expression, both RCU and DCU displayed lower levels 
than controls (Figure 2). This difference was only significant for RCU (26% lower than controls, 
r = 0.27, 95%IC = -0.94 to -0.22), although the effect size was comparable for DCU (24% lower 
than controls, d = 0.25, 95%IC = -1.00 to -0.05). However, when comparing the control group 
(n=60, mean=1.61, SD=0.76) with a combined cocaine user group (RCU and DCU) (n=88, 
mean=1.20, SD=0.64), we found a significantly lower level of NR3C1 mRNA expression in the 
user group (t [111.55] = 3.41, p<0.000, d=-0.57, 95%IC = -0.91 to -0.24), as published 
previously (Schote et al. 2019). In addition to that, similarly as already shown by Schote et al. 
(2019), Spearman rank correlations revealed that Cocainetotal was negatively correlated with 
NR3C1 mRNA expression in the DCU group (r=-.426, p<.05, n=30), but not in the RCU (r=.043, 
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p=.739, n=68). This finding was expected because, when compared to RCU, DCU showed larger 
variability in the estimated amount of cocaine consumed (Table S1).  
# Table 1 # 
# Figure 1 # 
# Figure 2 # 
Psychiatric Symptoms Severity and NR3C1 mRNA Expression over Time. 
The longitudinal linear mixed effect models for the SCL-90R scores and NR3C1 mRNA 
expression are shown in Table 2 (for mean and SD, please see Table S4). Regarding symptoms, 
we found significant time-group interaction effects, indicating that participants who decreased 
their consumption over time reported less severe SCL-90R scores regarding GSI (Figure 3a) 
(p=0.026), Depression (Figure 3b) (p=0.015), and Paranoid thoughts (Figure 3c) (p=0.027), 
suggesting that only this group changed over time when compared to increasers and controls. 
Concerning between group differences at baseline and follow-up, we found that, when compared 
to controls, CU who decreased their consumption reported higher scores at baseline for GSI 
(Figure 3a), Depression (Figure 3b) and Paranoid thoughts (Figure 3c), but no significant 
differences were found between both groups at follow-up.  
Although we did not find any other significant interaction effects, the data revealed a 
similar pattern for all symptoms, suggesting that CU who decreased their consumption tended to 
improve their symptom scores, while CU who increased their consumption within one year 
displayed worse or stable scores on the SCL-90R subscales (Figure S2 shows the PSI and the 
PDSI exemplarily). Interestingly, a group effect for CU who decreased their consumption was 
also found for GSI, PST, PSDI, Compulsiveness, Depression, Paranoid Thoughts, and 
Psychoticism scores, suggesting that they had more severe symptoms when compared to controls 
independently of the factor time. Similarly, we found a group effect for Aggressiveness, 
Compulsiveness, and Psychoticism scores for those participants who increased their 
consumption compared to controls. As published before (Hulka et al., 2015), we found 
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significant time-group interaction effect for several impulsivity scores although we used a 
slightly different set of predictors and firstly included treatment and ID as random effects.  
Spearman correlations (Table S3) revealed that changes in cocaine hair concentrations 
(Cocainetotal) were negatively correlated with changes in the SCL-90R GSI, anxiety, phobia and 
uncertainty to social contact symptoms scores within the cocaine decrease group, suggesting that 
cocaine users who reduced their consumption showed more psychiatric symptoms at the follow-
up. However, this correlation was driven by a single outlier with a very strong hair cocaine 
change score (-116.9 ng/mg) and a moderate increase in the SCL-90R scores (GSI change score 
+0.25). After exclusion of this participant no significant correlations between change in hair 
cocaine concentrations and SCL-90R scores remained in the decreasers group. Furthermore, 
SCL-90R somatization was positively associated with changes in cocaine hair concentrations 
within the cocaine increase group. Within all CU, changes in cocaine hair concentration were 
positively correlated with changes in the BIS total, attention impulsiveness, and motor 
impulsiveness scores as shown before (Hulka et al., 2015), indicating that decreased cocaine 
consumption went along with improvement of impulsive behaviour. Finally, again in all CU, the 
change in NR3C1 mRNA expression was negatively correlated with the total score of the BIS 
reflecting that increased glucocorticoid receptor gene expression was associated with reduced 
impulsivity (Table S3). As shown in Figure S4, no correlation was found between changes in 
cocaine hair concentration (Cocainetotal) and NR3C1 mRNA expression within all CU (r=-.125, 
p=.495, n=32), DCU (r=.042, p=.907, n=10), RCU (r=-.256, p=.248, n=22), increasers (r=-.205, 
p=.427, n=17), nor decreasers (r=-.046, p=.869, n=15).  
# Table 2 # 
# Figure 3 # 
In terms of NR3C1 mRNA expression a time-group interaction for those participants that 
decreased their consumption over time was found (Figure 4) (p=0.049), suggesting that 
participants who decreased their consumption over time were approaching similar levels of 
NR3C1 mRNA expression to controls at the follow-up (Table 2). We also found a negative 
group effect for both CU groups (Table 2), suggesting that CU have a downregulation of the 
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glucocorticoid receptor, as shown previously by Schote et al. (2019) for this sample. 
Furthermore, the negative time effect suggests that, when compared with baseline, all groups, 
including controls, displayed lower levels of NR3C1 mRNA expression (Table 2).  
Although the groups did not differ regarding age and sex, we performed the same 
analysis including both variables and years of education as covariates to control their effects on 
NR3C1 mRNA expression. Our findings revealed no effect for age, sex nor years of school 
education, but the time-group interaction for those participants that decreased their consumption 
over time was still observed (ß=.43, t[72] = 2.01, p<0.048). Additionally, because it has been 
recently shown that chronic alcohol consumption was associated with increased DNA 
methylation of the NR3C1 and reduced NR3C1 mRNA and protein expression levels in PFC 
(Gatta et al., 2019) and our groups differed concerning the current estimated amount of alcohol 
consumed during the week (in grams) (Table S2), we performed the same analysis including 
“alcohol grams per week” as a covariate. The model revealed no effect for “alcohol grams per 
week” (ß=.03, t[72] = 0.95, p<0.344), and the time-group interaction for those participants that 
decreased their consumption over time was still observed (ß=.44, t[72] = 2.06, p<0.042). 
Similarly, when investigating the effect of nicotine consumption in NR3C1 mRNA expression 
over time, no effect was found for years of consumption (ß=.02, t[72] = 0.64, p<0.521) and 
amount of cigarettes per day (ß=.03, t[72] = 1.093, p<0.277). Finally, when including years of 
cannabis consumption in the main model, we found no effect for cannabis (ß=.02, t[72] = -0.00, 
p<0.999) and the time-group interaction effect remained (ß=.43, t[72] = 1.99, p=0.050). Finally, 
because CU increasers and CU decreasers differed regarding the number of participants 
diagnosed with current cocaine dependency (Table S2), the main model was also performed 
including cocaine dependency (yes/no) as a covariate. No effect was found for cocaine 
dependency (ß=.03, t[72] = 0.21, p<0.832) and the interaction effect of time-group remained 
(ß=.43, t[72] = 2.00, p<0.048) (Figure S3 shows a linear mixed effect model performed 
including controls, RCU and DCU as a predictor, no time-group interaction effect was found). 
# Figure 4 # 
Discussion 
In this study, changes in cocaine consumption over a period of one year were linked with 
changes in psychiatric symptoms and NR3C1 receptor gene expression. At baseline we found 
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that severity of cocaine use was related to severity of psychiatric symptoms, including 
impulsivity, and lower expression of the NR3C1 glucocorticoid receptor gene. Accordingly, 
DCU reported higher levels of psychiatric symptoms than controls, while RCU were 
intermediate. CU, in general, showed lower levels of NR3C1, as found previously (Schote et al., 
2019). However, post hoc analysis revealed a significant effect only for RCU on NR3C1 gene 
expression. This is, nonetheless, well-explained by a reduction in statistical power, as the number 
of participants in the DCU group was considerably smaller (RCU, n=68; DCU, n=30) and DCU 
(r = 0.25) did display a similar effect size level to RCU (r =0.27). These similar effect sizes in 
NR3C1 expression are surprising only at a first glance, as there was considerable overlap in the 
current cocaine use severity between RCU and DCU, thus confirming that the dependency 
criterion is not directly related to the amount of substance consumed (APA., 2013). The large 
within-group variability observed in the DCU may also explain why we found a negative 
correlation between NR3C1 expression and cocaine hair concentrations only in this group. 
Together, our NR3C1 findings are in line with our previous studies reporting that higher cocaine 
levels measured in hair correlate with lower NR3C1 mRNA expression, suggesting an adaptive 
mechanism of cocaine dose-dependent transcriptional regulation. Therefore, our findings may 
support the idea that the cocaine-induced increase in cortisol levels (Baumann et al., 1995), 
which might lead to a sensitization of the receptor and, via feedback mechanisms, to a 
downregulation of NR3C1 expression.  
At follow-up, we first showed that cocaine users who decreased their cocaine 
consumption over time reported fewer psychiatric symptoms when compared to controls and CU 
who increased their cocaine use over time. These findings are independent of any treatment 
attendance. In the context of other substance use disorders, our results can be compared with 
another study in 26 adolescent cannabis users showing that a 28-day cannabis abstinence was 
associated with strong reductions in depressive symptoms at follow-up (Jacobus et al., 2017). 
Previously, Haasen et al. (2005) have shown that the intensity of cocaine use predicts worse 
mental health; however, the authors did not investigate whether the attenuation of use might 
predict better mental health. Interestingly, we found that CU who decreased consumption 
generally reported more severe symptoms at baseline. This finding suggests that a higher burden 
of psychiatric symptoms is likely a motivation to reduce consumption, given that the participants 
who reported fewer symptoms tended to maintain their consumption pattern or increase it.  
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Concerning NR3C1 expression, our main longitudinal findings revealed that CU who 
decreased their cocaine consumption over time did not decrease in their NR3C1 expression at 
follow-up as much as controls and CU who increased their cocaine use over time. The significant 
difference between decreasers and controls at baseline (effect size r=0.48) disappeared at follow-
up (r=.24), while this difference remained stable and significant between increasers and controls 
at both time points (r=0.34). Further analyses suggest that the time-group interaction effect was 
not driven by nicotine, alcohol, or cannabis consumption; neither by cocaine dependency 
diagnosis nor seasonal factor. Additionally, the time-group interaction effect seemed to be 
exclusive to the NR3C1 gene expression, since no time-group interaction effect was found for 
any of the reference genes. In general terms, these findings also seem to be in accordance with 
our interpretation of the previously demonstrated dose-response relationship between severity of 
cocaine use and NR3C1 expression as a drug-induced effect (Schote et al., 2019). As discussed in 
Schote et al. (2019), it seems reasonable that the chronic cortisol secretion induced by cocaine 
(Baumann et al., 1995) in combination with elevated psychological stress levels (as described 
here) result in a down-regulation of the receptor (McGowan et al., 2009; Spindola et al., 2017). 
The glucocorticoid receptor plays a crucial role in the feedback regulation of the HPA axis 
(Deroche-Gamonet et al., 2003), while chronic exposure to stress (e.g., induced by psychiatric 
symptoms) can also lead to adaptations in this system. This may explain the lack of a significant 
correlation between changes in NR3C1 expression and changes in cocaine hair concentration, 
given that we found that CU who decreased their consumption over time had already reported 
higher psychiatric symptoms and had lower levels of NR3C1 expression at baseline when 
compared with the other groups.  
Nevertheless, the fact that no correlation was found concerning changes in NR3C1 
expression and changes in cocaine hair concentration may also be explained by the reduced 
number of participants at follow-up (decreasers, n=16 and increasers, n=18) and a strong effect 
of time found in the linear mixed model (r=.615, p=.000). While the convergence of NR3C1 
expression levels between controls and CU who decreased their consumption might suggest a 
normalization of NR3C1 gene expression in cocaine decreasers, the precise effect of cocaine on 
NR3C1 levels requires further investigation. Surprisingly, we observed that controls also 
displayed much lower levels of NR3C1 expression at follow-up. However, this observation may 
be explained by a general habituation effect to the novel environment of a psychological test 
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setting. In other words, when participants arrived in the hospital to perform the 1-year follow-up, 
the environment, research team, and the test procedures were already familiar to them and, thus, 
perceived as less stressful overall. Additionally, the normalization procedure on the reference 
genes using the qBase plus software does correct for any possible changes induced by total RNA 
amount (e.g., cell count), reinforcing that the observed changes in NR3C1 gene expression 
reflect actual changes in the level of expression between baseline and follow-up induced by e.g., 
general habituation effects, changes in cocaine consumption, or so far unknown factors. Future 
studies might consider experimental stress induction challenges to elucidate the effect of changes 
in cocaine consumption on the HPA stress-response system and glucocorticoid receptor 
expression.  
In line with the above interpretation, we also found that both increased NR3C1 gene 
expression and decreased cocaine consumption during the study interval were associated with 
improvements in self-reported impulsivity across all CU. Taking together the high vulnerability 
for relapse that has been reported in CU – which can be understood as a lack of behavioural 
inhibition – and both the acute and chronic effects of regular cocaine intake (Fox et al., 2009; 
Grassi-Oliveira et al., 2012; McReynolds et al., 2014), these correlations may reinforce the role 
of glucocorticoid receptor expression in the vulnerability to relapse via increased impulsivity 
(Maniaci et al., 2018). Hence, our findings are in line with preceding analyses of this sample 
showing that cognitive impairments and elevated impulsivity were partially cocaine-induced and 
potentially reversible (Hulka et al., 2015; Vonmoos et al., 2014). However, the correlational 
nature of these findings does not allow us to provide further interpretation on the causal 
relationship between changes in NR3C1 expression or cocaine consumption and self-reported 
impulsivity.  
Our results might be interpreted in light of some limitations. Although we were able to 
assess a relatively large number of cocaine users twice with a 1-year interval, our sample size 
remained moderate for longitudinal analysis with a three-group design, which could thus 
possibly be underpowered. Moreover, given the small number of participants who attended any 
kind of treatment between baseline and follow-up (approximately 40% in each CU group), we 
were unable to make a clear distinction between types and intensity of treatments such as 
ambulatory or inpatient units. However, it must be highlighted that it was not the main goal of 
the present study to investigate the effect of a specific treatment on psychiatric symptoms. 
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Additionally, glucocorticoid receptor gene expression was measured in blood, which may not 
exactly reflect expression at the neuronal level. Nevertheless, correlated expression in blood and 
brain have been reported (Daskalakis et al., 2014), allowing at least partial interpretative transfer 
from the periphery to central brain functions.  
Our longitudinal study investigated, for the first time, the link between changes in 
cocaine use over a 1-year period, psychiatric symptoms, and NR3C1 expression levels. Based on 
hair toxicology analyses, we were able to ensure the inclusion of participants with little or no 
polysubstance use and to quantify changes in drug use over time Our main findings are: (a) CU 
reported higher levels of psychiatric symptoms and psychological distress compared to controls, 
while this effect was strongly pronounced in DCU; (b) objective changes in cocaine consumption 
were related to changes in psychiatric symptoms, specifically in depressive and paranoid 
symptoms; (c) changes in cocaine use severity are potentially associated with changes in 
glucocorticoid receptor expression, supporting the hypothesis that NR3C1 expression can, at 
least partially, be impacted by chronic cocaine exposure; and (d) longitudinal changes in 
glucocorticoid receptor expression were negatively correlated with changes in self-reported 
impulsivity, indicating that at least some cocaine-related psychiatric symptoms are explainable 
by substance-induced adaptions of the HPA axis. 
Taken together, our findings suggest that both cocaine-related adaptations of the HPA 
axis and increased psychological distress can be partially reversible after discontinuation of drug 
use. This information can be given to users at the beginning of treatment as an incentive to 
reduce cocaine consumption. Nevertheless, our conclusions should be further investigated in 
future longitudinal studies with larger samples sizes.  
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Table 1.  
Psychiatric symptoms and mRNA expression at baseline.
Controls (n=68) RCU (n=68) DCU (n=30) F df, dferr p pη2 
BIS subscales 
 Total Score a 63.40 (9.35) 68.68 (10.24) ** 73.30 (12.66) *** 10.42 2, 165 .000 .113 
 Attention Impulsiveness a 14.66 (3.07) 16.35 (3.91) * 18.60 (4.13) *** + 12.55 2, 165 .000 .133 
 Motor Impulsiveness a 22.49 (3.87) 24.38 (4.46) * 25.77 (5.82) ** 6.27 2, 165 .002 .071 
 Non-planning Impulsiveness a 26.25 (4.73) 27.94 (4.07) 28.93 (4.91) * 4.43 2, 165 .013 .052 
SCL-90R subscales 
 GSI 0.30 (0.27) 0.51 (0.44) ** 0.79 (0.54) *** ++ 15.85 2, 165 .000 .163 
 PSDI 1.18 (0.41) 1.41 (0.40) ** 1.72 (0.44) *** ++ 18.12 2, 165 .000 .182 
 PST 20.28 (0.41) 29.29 (1.41) ** 38.63 (18.94) *** + 11.92 2, 165 .000 .128 
 Aggressiveness 0.24 (0.27) 0.59 (0.69) *** 0.74 (0.70) *** 10.72 2, 165 .000 .116 
 Anxiety 0.25 (0.31) 0.50 (0.52) * 0.78 (0.69) *** + 12.59 2, 165 .000 .134 
 Compulsiveness 0.38 (0.42) 0.64 (0.55) * 0.97 (0.68) *** + 13.30 2, 165 .000 .140 
 Depressive symptoms 0.44 (0.48) 0.66 (0.60)  1.00 (0.77) *** + 9.41 2, 165 .000 .104 
 Paranoid thoughts 0.37 (0.43) 0.59 (0.59) 0.87 (0.68) 8.72 2, 165 .000 .097 
 Phobia 0.11 (0.18) 0.20 (0.34) 0.37 (0.59) ** 5.52 2, 165 .005 .063 
 Psychoticism 0.14 (0.20) 0.32 (0.38)  0.53 (0.49) 13.77 2, 165 .000 .145 
 Somatization 0.21 (0.20) 0.35 (0.40) * 0.60 (0.48) *** ++ 12.68 2, 165 .000 .135 
 Uncertainty to social contact 0.39 (0.45) 0.52 (0.58) 0.87 (0.80) ** + 6.41 2, 165 .001 .079 
mRNA expression 
 NR3C1 1.60 (0.76) 1.19 (0.65) * 1.22 (0.60) 6.20 2, 148 .003 .079 
Means and standard deviations. Significant Sidak post hoc test v. control group: *p<.05; **p<.01; ***p<.001; Significant Sidak post hoc test 
v. RCU group: +p<.05; ++p<.01; a Data already published by Vonmoos et al. (2013). Barratt Impulsiveness Scale (BIS), recreational cocaine
users (RCU), dependent cocaine users (DCU), Symptom Checklist-90-R (SCL-90R), Global Severity Index (GSI), Positive Symptoms Total 
(PST), and Positive Symptom Distress Index (PSDI). Due to missing data, samples for NR3C1 mRNA expressions are not equal as SCL-90R 
subscales (RCU = 65, DCU = 27, Controls = 60). 
Table 2.  
Summary of the generalized linear mixed effect models. 
Fixed Effects Random Effects 
Increaser (n=19) Decreaser (n=19) Time  Increase:Time Decrease:Time Treatment/ID 
BIS subscales 
 Total Score a 4.02 (1.46) 7.52 (2.68) ** 0.10 (0.11) 2.59 (1.48) -4.49 (-2.56) * 0.07 
 Attention Impulsiveness a 1.49 (1.57) 1.93 (1.99) * 0.27 (0.71) 0.85 (1.17) -0.99 (-1.36) 0.06 
 Motor Impulsiveness a 0.97 (0.87) 2.91 (2.54) ** -0.60 (-1.17) 1.81 (1.85)  -2.00 (-2.04) * 0.07 
 Non-planning Impulsiveness a 1.54 (1.34) 2.66 (2.27) * 0.43 (1.12) -0.10 (-0.13) -1.49 (-1.99) * 0.04 
SCL-90R subscales 
 GSI 0.13 (1.43) 0.24 (2.57) * -0.03 (-0.84) 0.02 (0.35) -0.17 (-2.26) * 0.08 
 PST 6.54 (1.54) 11.11 (2.56) * -2.77 (-1.53) 3.57 (1.04) -4.39 (-1.27) 0.07 
 PSDI 0.12 (1.13) 0.25 (2.32) * 0.00 (0.08) -0.00 (-0.07) -0.20 (-1.81) 0.11 
 Aggressiveness 0.30 (2.16) * 0.24 (1.73) -0.02 (-0.34) -0.18 (-1.16) -0.22 (-1.40) 0.11 
 Anxiety 0.13 (1.27) 0.17 (1.58) -0.01 (-0.21) 0.01 (0.15) -0.05 (-0.59) 0.10 
 Compulsiveness 0.25 (2.18) * 0.41 (3.47) *** -0.04 (-0.90) 0.13 (1.32) -0.18 (-1.87) 0.10 
 Depressive symptoms 0.20 (1.36) 0.38 (2.55) * -0.03 (-0.42) 0.01 (0.13) -0.33 (-2.48) * 0.06 
 Paranoid thoughts 0.09 (0.62) 0.39 (2.65) ** -0.06 (-0.93) -0.06 (-0.53) -0.28 (-2.24) * 0.10 
 Phobia 0.04 (0.62) 0.06 (0.87) -0.05 (-1.53) 0.09 (1.27) 0.02 (0.37) 0.21 
 Psychoticism 0.17 (2.43) * 0.26 (3.48) *** -0.02 (-0.72) 0.01 (0.29) -0.10 (-1.64) 0.14 
 Somatization 0.08 (0.97) 0.14 (1.72) 0.00 (0.12) 0.04 (0.62) -0.11 (-1.45) 0.08 
 Uncertainty to social contact 0.04 (0.35) 0.25 (1.78) -0.10 (-1.75) -0.04 (-0.36) -0.17 (-1.60) 0.00 
mRNA expression 
 NR3C1  -0.40 (-2.68) ** -0.57 (-3.67) *** -0.75 (-6.62) *** 0.19 (0.92) 0.43 (1.97) * 0.27 
 ACTB -0.05 (-0.54) -0.09 (-0.89) 0.01 (0.25) 0.17 (1.23) 0.24 (1.66) 0.05 
 ALAS1 0.05 (0.73) -0.00 (-0.10) -0.06 (-0.01) 0.00 (0.08) -0.04 (-0.41) 0.02 
 GAPDH 0.06 (1.05) 0.08 (1.40) -0.19 (-5.00) *** -0.04 (-0.61) -0.08 (-1.14) 0.40 
 PPIA -0.09 (-1.16) 0.00 (0.01) 0.28 (4.69) *** -0.13 (-1.18) -0.10 (-0.86) 0.18 
For fixed effects: coefficient (t-value) reported. * p<0.05; ** p<0.01; *** p<0.001. For random effects: conditional pseudo R
2 value were estimated by subtracting 
the conditional pseudo R2 value associated with the random effects of a null model from the conditional pseudo R2 value associated with fixed effects plus the 
random effects of the tested model. 
a
 Data already published by Hulka et al. (2015) but with different predictors and reference groups. Symptom Checklist-90-R 
(SCL-90R), Global Severity Index (GSI), Positive Symptoms Total (PST), and Positive Symptom Distress Index (PSDI). Participant identification number (ID). 
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Figure 1. Differences in SCL-90R Global Severity Index (GSI) subscale between controls and 
cocaine users. 
Significant Sidak post hoc test: *p<.05; **p<.01; ***p<.001. 
Figure 2. Differences in NR3C1 mRNA expression between controls and cocaine users. 
For Student t-test, p values: * p<.05; *** p<.001. 
Figure 3. Differences in psychiatric severity symptoms between controls and cocaine users for 
generalized linear mixed effect models.  
For Linear Mixed Models: + Time-group interaction, p<.05. For Student t-test, p values: * p<.05; 
** p<.01. Effect sizes were calculated by Pearson’s correlation coefficient. 
Figure 4. Differences in the expression of NR3C1 between controls and cocaine users.  
For Linear Mixed Models: + time-group interaction, p<.05. For Student t-test, p values: * p<.05; 















































Additional analysis on NR3C1 mRNA Expression over Time.
Because gene expression can be influenced by seasonal variation (Goldinger et al., 2015), 
we also performed the main model including season (4 levels factor variable) as a covariate. The 
model revealed no effect for season and the interaction effect of time-group was still observed 
(ß=.48, t [70] = 2.23, p<0.028). Furthermore, to investigate whether the time-group interaction 
was specifically observed in NR3C1 mRNA expression, similar longitudinal linear mixed effect 
models were performed for the four reference genes (i.e., ACTB, ALAS1, GAPDH, and PPIA). 
As shown in Table 2, no time-group interaction for those participants that decreased their 
consumption over time was found. However, a positive effect for time was observed for PPIA 
gene expression (ß =0.28, t[73]=4.69, p<0.001), suggesting that all groups increased the 
expression of this gene; and an a negative effect for time was observed for GAPDH gene 
expression (ß =-0.19, t[73]=-5.00, p<0.001), suggesting that all groups decreased the expression 
of this gene.  
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 Age, y 30.3 (9.2) 28.7 (6.2) 32.5 (9.0) F=2.00 2, 163 .13 
 Sex (f/m)  21 / 47 18 / 50 8 / 22 x²=0.38 2 .83 
 Verbal IQ (MWT-B) 104.4 (9.7) 103.2 (9.6) 99.7 (9.1) F=2.46 2, 163 .09 
  School education, y 10.7 (1.8) 10.5 (2.0) 9.5 (1.2) ** ++ F=4.82 2, 163 >.05 
 Craving for cocaine (0-70) - 19.0 (9.1) 20.3 (11.4) t=0.60 1, 96 .55 
Cocaine 
 Grams per week a - 1.1 (1.4) 7.9 (15.8) - - - 
 Years of use - 6.5 (4.0) 9.4 (6.5) - - - 
 Cumulative dose (g) - 519.7 (751.2) 5500.9 (9635.2) - - - 
 Last consumption (days) - 27.5 (37.6) 21.0 (33.6)  - - - 
 Hair analysis cocaine (ng/mg) - 2.7 (4.6) 22.2 (32.6)  - - - 
 Hair analysis benzoylecgonine (ng/mg) - 0.6 (0.9) 5.1 (7.7) - - - 
 Hair analysis cocaethylene (ng/mg) - 0.3 (0.3) 2.0 (3.7) - - - 
 Hair analysis norcocaine (ng/mg) - 0.1 (0.1) 0.6 (0.8) - - - 
 Hair analysis cocainetotal (ng/mg) - 3.4 (5.6) 27.8 (40.2) - - - 
 Urine toxicology (n/p) b 68 / 0 57 / 10 18 / 12 x²=29.07 2 >.00
Other substance use 
 Nicotine smoking (y/n)  53 / 15 53 / 15 24 / 6 x²=0.06 2 0.97 
 Nicotine cigarettes per day a 9.3 (9.5) 11.7 (8.7) 15.7 (13.5) F=4.21 2 >.05
 Nicotine years of use 9.1 (9.2) 9.6 (6.3) 14.1 (9.3) F=4.26 2 >.05
 Alcohol grams per week a 116.8 (122.6) 167.2 (116.6) 188.5 (260.6) F=2.94 2 0.05 
 Alcohol years of use 13.2 (9.3) 11.2 (5.0) 13.5 (9.4) F=1.37 2 0.25 
 Cannabis grams per week a 0.4 (0.9) 0.8 (2.0) 1.2 (3.7) F=1.53 2 0.21 
 Cannabis years of use 4.6 (6.5) 7.6 (6.0) 10.5 (9.9) F=7.85 2 >.00
Means and standard deviations. Significant p values are shown in bold. Sex and smoking are shown in frequency data. Significant Sidak post 
hoc test vs. control group: *p<.05; **p<.01; ***p<.001; Recreational cocaine users (RCU), dependent cocaine users (DCU). Significant Sidak 
post hoc test vs. RCU group: ++p<.01. a Average use during the last 6 months. b Urine toxicology (neg/pos) are based on cut-off value for 
Cocaine = 150 ng/ml and for Tetrahydrocannabinol 50 ng/ml (Substance Abuse and Mental Health Services Administration, 2008). Complete 
Data published on Vonmoos et al. (2013). 
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Table S2.  
Drug consumption pattern at baseline and follow-up. 



























Age, y 30.3 (8.9) 31.5 (9.4) 31.4 (8.3) .20 b 2,83 .82 pη2=.00  - - - - - - - 
Sex (f/m)  16/32 3/16 5/14 2.11c 2 .35 V=.16 - - - - - - - 
Verbal IQ (MWT-B) d 107.6 (10.0) 102.9 (9.7) 103.8 (7.1) 2.20 b 2,83 .12 pη2=.05  - - - - - - - 
Education, y 10.8 (1.8) 10.4 (1.8) 10.0 (1.5) 1.30 b 2,83 .28 pη2=.03  - - - - - - -
Weeks between t1 and t2 58.2 (10.1) 59.3 (12.1) 61.9 (14.5) .69 b 2,83 .50 pη2=.02  - - - - - - - 
Season at measurement time i 8/5/16/19 5/3/6/5 4/6/6/3 - - - -  11/8/12/17 5/4/4/6 2/12/4/1 - - - - 
Cocaine 
  Times per week e - 1.6 (1.8) 1.0 (1.3) 1.17 f 36 .25 d=.38 - 1.1 (0.8) 0.3 (0.3) 3.85 f 36 <.001 d=1.32 
  Grams per week e - 2.0 (2.5) 1.7 (2.3) .41f 36 .68 d=.12 - 1.6 (2.5) 0.4 (0.4) 2.18 f 36 .04 d=.67 
  Years of use - 7.0 (5.5) 8.2 (5.4) .68 f 36 .50 d=.22 - 8.9 (5.4) 9.7 (5.2) .45 f 36 .65 d=.15 
  Cumulative dose (grams) e - 1182 (1635) 3698 (8585) 1.25 f 36 .22 d=.41 - 91 (119) 49 (89) 1.25 f 36 .22 d=.40 
  Last consumption (days) - 18.5 (25.1) 16.8 (14.6) .29 f 36 .77 d=.08 - 7.0 (6.3) 81.4 (145.1) 2.23 f 36 .03 d=.72 
  Hair analysis (ng/mg) 
    Cocainetotal - 10.3 (29.2) 14.9 (32.2) .46 
f 36 .65 d=.15 - 40.7 (76.1) 4.2 (8.2) 2.08 f 36 .05 d=.67 
    Cocaine - 8.2 (23.3) 11.4 (23.9) .42 f 36 .68 d=.14 - 31.7 (56.5) 3.1 (5.9) 2.19 f 36 .03 d=.71 
    Benzoylecgonine  - 1.9 (5.5) 3.1 (7.6) .58 f 36 .56 d=.18 - 8.3 (19.6) 1.0 (2.2) 1.62 f 36 .11 d=.52 
    Cocaethylene - 1.0 (2.8) 0.9 (2.8) .11 f 36 .91 d=.04 - 1.2 (2.1) 0.3 (1.0) 1.56 f 36 .13 d=.55 
    Norcocainet - 0.2 (0.5) 0.4 (0.8) .83 
f 36 .41 d=.30 - 0.6 (1.4) 0.1 (0.1) 1.71 f 36 .10 d=.50 
  Urine toxicology (n/p) g 48/0 14/5 16/3 .63 f 1 .43 V=.13 48/0 7/12 18/1 14.15 c 1 <.001 V=.61 
  Dependency (DSM-IV) (y/n) - - - - - - - - 10/9 2/17 7.79 1 <.01 V=.03    
Alcohol
  Grams per week g 119.9 (136.8) 169.4 (129.2) 155.3 (146.4) 1.07 b 2,83 .35 pη2=.03 104.3 (88.6) 259.7 (244.5) *** 127.4 (141.4) + 7.71b 2,83 <.001 pη2=.16 
  Years of use 13.3 (8.8) 13.7 (7.6) 12.0 (7.3) .23 b 2,83 .79 pη2=.01 14.0 (8.7) 14.8 (7.5) 12.6 (7.9) .34 b 2,83 .71 pη2=.01 
Nicotine
  Smoking (y/n) g 37/11 14/5 14/5 .13 c 2 .94 V=.04 40/8 15/4 13/6 1.83 c 2 .40 V=.15 
  Cigarettes per day g 8.7 (8.7) 12.8 (11.2) 9.5 (8.2) 1.38 b 2,83 .26 pη2=.03 8.2 (8.7) 13.4 (12.0) 8.2 (7.8) 2.31 b 2,83 .11 pη2=.05 
  Years of use 9.3 (8.3) 10.4 (8.9) 12.7 (10.3) .95 b 2,83 .39 pη2=.02 10.5 (8.8) 12.5 (8.6) 12.6 (9.9) .56 b 2,83 .57 pη2=.01 
Cannabis
  Grams per week g 0.6 (1.6) 3.3 (8.9) 1.2 (2.3) 2.38 b 2,83 .10 pη2=.05 0.5 (1.6) 2.1 (4.6) 1.1 (2.7) 2.28 b 2,83 .11 pη2=.05 
  Years of use 4.5 (4.9) 9.5 (8.5) * 10.1 (9.7) * 5.92 b  2,83 .004 pη2=.12 4.6 (5.9) 10.5 (9.8) * 8.6 (9.7) 4.64 b 2,83 .01 pη2=.10 
  Cumulative dose (grams)  980 (3985) 3199 (5899) 2606 (6359) 1.61b 2,83 .21 pη2=.04 53.4 (180) 217.8 (526.5) 84.7 (189.6) 2.15 b 2,83 .12 pη2=.05 
Note. Means and SD. Significant p values are shown in bold. 
a
Parameters at follow-up refer to the 1-year period between t1 and t2. 
b
ANOVA (all groups, with significant Sidak post hoc test vs control group: p<0.05; 




-test (all groups/cocaine users only) for frequency data. 
d
Verbal IQ was assessed by the Mehrfachwahl Wortschatz Intelligenztest (Lehrl, 1999). 
e
Average use during the last 6 months. 
f
Independent t-test (cocaine users only). 
g
Urine toxicology (neg/pos) are based on cutoff value for Cocaine 1⁄4 150 ng/ml and for Tetrahydrocannabinol 50 ng/ml (Substance Abuse and 
Mental Health Services Administration, 2008). The w
2
-test for cocaine includes only cocaine users, the w
2
-test for cannabis includes controls and cocaine users. 
h
Last consumption is averaged only for persons who used the 




Spearman correlations between changes in cocaine consumption, mRNA expression, symptoms and impulsiveness. 
Increaser Decreaser Both groups
Cocainetotal NR3C1  Cocainetotal NR3C1 Cocainetotal NR3C1 
SCL-90R subscales changes scores
 GSI -.479 * 
 PSDI .408 -.451 
 PST .283 
 Aggressiveness 
 Anxiety -.509 * 
 Compulsiveness .292 
 Depressive symptoms 
 Paranoid thoughts 
 Phobia .438 -.578 ** 
 Psychoticism  
 Somatization .575 * -.417 
 Uncertainty to social contact -.466 * 
Impulsivity changes scores 
 BIS Total Score .414 * -.344 * 
 BIS Attention Impulsiveness .344 * 
 BIS Motor Impulsiveness .335 * -.308 
 BIS Non-planning Impulsiveness 







Means and standard deviation of the main outcome variables. 
  Baseline   Follow-up 
 Control Increaser Decreaser  Control Increaser Decreaser 
BIS subscales        
     Total Score a 63.98 (8.61) 68 (14.27) 72.63 (10.10)  64.08 (8.9) 70.61 (11.83) 67.16 (9.66) 
     Attention Impulsiveness a 14.40 (3.31) 15.89 (4.57) 16.42 (3.58)  14.67 (2.76) 17.06 (4.26) 15.58 (3.66) 
     Motor Impulsiveness a 22.92 (3.61) 23.89 (5.84) 26 (2.29)  22.31 (3.70) 25 (4.31) 23.37 (4.04) 
     Non-planning Impulsiveness a 26.67 (3.83) 28.21 (5.14)   27.10 (3.92)   
SCL-90R subscales        
     GSI .28 (.25) .51 (.48) .62 (.39)  .25 (.25) .50 (.39) .42 (.34) 
     PSDI 1.18 (.38) 1.42 (.40) 1.55 (.42)  1.18 (.41) 1.41 (.32) 1.35 (.31) 
     PST 18.79 (12.46) 29.05 (19.21) 33.58 (15.67)  16.02 (12.64) 29.61 (17.34) 26.21 (15.86) 
     Aggressiveness .23 (.24) .77 (.97) .76 (.76)  .20 (.23) .53 (.56) .46 (.55) 
     Anxiety .23 (.27) .45 (.49) .48 (.40)  .22 (.32) .46 (.42) .43 (.44) 
     Compulsiveness .33 (.37) .59 (.56) .75 (.55)  .29 (.30) .67 (.50) .52 (.46) 
     Depressive symptoms .39 (.46) .73 (.63) .90 (.66)  .36 (.42) .72 (.53) .52 (.55) 
     Paranoid thoughts .32 (.38) .50 (.69) .79 (.59)  .25 (.48) .32 (.39) .43 (.55) 
     Phobia .14 (.20) .18 (.30) .19 (.32)  .08 (.22) .21 (.34) .17 (.25) 
     Psychoticism  .11 (.16) .29 (.48) .36 (.33)  .09 (.13) .28 (.40) .23 (.27) 
     Somatization .22 (.21) .40 (.43) .46 (.35)  .22 (.20) .46 (.47) .37 (.26) 
     Uncertainty to social contact .36 (.43) .50 (.65) .69 (.59)  .25 (.38) .36 (.63) .42 (.42) 
mRNA expression        
     NR3C1 1.57 (.68) 1.17 (.71) 1.01 (.59)  .82 (.36) .61 (.35) .68 (.32) 
     ACTB 1.04 (1.04) .98 (.27) .94 (.25)  1.06 (.42) 1.18 (.37) 1.21 (.43) 
     ALAS1 1.04 (.22) 1.10 (.24) 1.06 (.32)  1 (.34) 1.15 (.74) .93 (.22) 
     GAPDH 1.05 (.16) 1.13 (.23) 1.2 (.49)  .88 (.22) .90 (.25) .85 (.13) 
     PPIA 1.01 (.36) .90 (.23) 1 (.32)  1.32 (.38) 1.07 (.35) 1.19 (.30) 
Note. a Data already published by Hulka et al. (2015); 
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Figure S1. Hair concentration cocainetotal in three cocaine user groups at baseline and one-year follow-up. 
Hair concentration cocainetotal (ng/mg) in cocaine user groups. Means and standard deviation. A mixed 
design analysis (ANOVA) showed a significant time-group interaction effect (F[2,54]=5.70, p<.10). 
Significant Sidak post hoc test ** p<.01. Data already published on Vonmoos et al. (2014). 
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Figure S2. Differences in psychiatric severity symptoms between 
controls and cocaine users for generalized linear mixed effect models. 
Effect sizes were calculated by Pearson’s correlation coefficient. 
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Figure S3. Differences in NR3C1 mRNA expression between 
controls and cocaine users. No difference between DCU and 
RCU was found, neither time-group effect when performing a 
generalized linear mixed effect model.
Figure S4. Scatter plot of changes in cocaine hair concentration (Cocainetotal) and NR3C1 mRNA 
expression. No significant correlation was found within all cocaine users (r=-.125, p=.495, n=32), 
DCU (r=.042, p=.907, n=10), RCU (r=-.256, p=.248, n=22), increasers (r=-.205, p=.427, n=17), nor 
decreasers (r=-.046, p=.869, n=15).  
